BioXcel Therapeutics (NASDAQ:BTAI) Downgraded to “Hold” at ValuEngine

ValuEngine lowered shares of BioXcel Therapeutics (NASDAQ:BTAI) from a buy rating to a hold rating in a research report report published on Monday morning, ValuEngine reports.

Several other analysts also recently weighed in on BTAI. HC Wainwright reiterated a buy rating on shares of Zomedica Pharmaceuticals in a research report on Wednesday, June 5th. Zacks Investment Research upgraded GCP Applied Technologies from a sell rating to a hold rating in a research report on Friday, May 31st.

NASDAQ:BTAI opened at $10.87 on Monday. BioXcel Therapeutics has a twelve month low of $2.41 and a twelve month high of $12.16. The company has a market capitalization of $170.60 million, a P/E ratio of -8.23 and a beta of 3.04. The stock’s fifty day simple moving average is $10.89. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.59 and a current ratio of 5.59.

BioXcel Therapeutics (NASDAQ:BTAI) last released its earnings results on Tuesday, May 7th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.02. On average, analysts forecast that BioXcel Therapeutics will post -2.19 EPS for the current fiscal year.

A hedge fund recently bought a new stake in BioXcel Therapeutics stock. Creative Planning acquired a new stake in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned 0.20% of BioXcel Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 16.05% of the company’s stock.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Recommended Story: What is a balanced fund?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with's FREE daily email newsletter.